Hervey Bay Herbal Medicine

09/06/2026

You have heard that fructose causes fatty liver. That part is true. What is less known is that your gut gets the first attempt at clearing it, and that step can be changed.

Fructose is broken down by your gut and your liver. In excess, the liver converts it into new fat, and over time that becomes fatty liver disease. The usual advice is to cut the sugar.

A 2025 study in mice found a second lever. Researchers fed the animals the fibre inulin and used a labeled tracer to follow where the fructose went.

The fibre did not change how much fructose reached the gut. It did not change how the mouse itself processed sugar. It changed the bacteria.

Fed inulin, the gut microbiome broke fructose down in the small intestine before it could spill over to the liver. Same fructose in, far less reaching the liver. A key species behind this was Bacteroides acidifaciens, and the effect transferred through the microbiome alone.

In these mice, the result was less liver fat, better insulin sensitivity, and reduced fibrosis.

This is a mouse study. No human trial has tested it. Fibre is good for people for many reasons, but this specific mechanism, gut bacteria intercepting fructose before the liver sees it, has not been shown in humans.

It changes how you think about the problem. Fatty liver is not only about how much sugar you eat. It is about which microbes meet that sugar first. The fibre is not feeding you. It is feeding the bacteria that clear your sugar.

Jung et al., Nature Metabolism, 2025

06/06/2026

02/06/2026

Most people think of magnesium and blood sugar as two unrelated things. Inside your cells, they are tied together.

Insulin is often described as a key that lets sugar into your cells. That is true, but it skips a step. Insulin does not open the door itself. It lands on the outside of the cell and signals that sugar is waiting. The cell then has to do the actual work of opening the door, and that work runs on energy.

That energy is ATP, the cell's power currency. And ATP only functions when it is paired with magnesium. Magnesium is the partner that lets the cell spend energy. Without it, the cell gets insulin's message but does not have the power to act on it. The door opens slowly, or barely, and sugar stays in the bloodstream longer than it should.

This is one of the quiet reasons low magnesium and high blood sugar travel together. When a cell ignores insulin's signal, that is called insulin resistance, and weak magnesium-powered energy transfer is part of what is physically happening underneath that word.

There is also a loop worth knowing. Insulin is what pulls magnesium into your cells in the first place. So when cells stop responding to insulin well, they pull in less magnesium, which leaves even less to power the response. Each problem deepens the other.

Now the honest part, because this gets oversold. This is not a claim that magnesium pills fix blood sugar. Most of the evidence is from observation and lab work, and the clearest signal shows up in people with type 2 diabetes, who often run low on cellular magnesium. In people who already have enough, taking more does not appear to add a benefit. And a normal magnesium blood test does not rule the problem out, because less than one percent of your body's magnesium is in your blood. The level inside your cells, where insulin actually does its work, can be low while your blood test looks fine.

The point is simple. Insulin sends the message. Magnesium powers the cell's ability to answer it. Without enough, the message lands but the cell cannot fully respond.

Kostov K. Int J Mol Sci. 2019 de Sousa Melo SR, et al. Biol Trace Elem Res. 2022 Takaya J, et al. Magnes Res. 2004 Barbagallo M, Dominguez LJ. Arch Biochem Biophys. 2006

20/05/2026

A pilot clinical study evaluated a traditional dried rosemary leaf (Rosmarinus officinalis) infusion in untreated grade 1 hypertensive patients (defined as systolic BP 140 to 159 mmHg and/or diastolic BP 90 to 99 mmHg) using a pragmatic but loosely controlled design. Over 45 days, participants consumed a daily tea made from 2 g powdered rosemary leaf infused in 100 mL hot water for 15 minutes, delivering approximately 38 mg polyphenols including 18 mg of rosmarinic acid. The use of powdered leaf is noteworthy, as it substantially increases extraction yield compared with intact leaf.

In the hypertensive group (n=30 completers), the herbal intervention produced statistically significant reductions in ambulatory blood pressure, including −6.3 mmHg systolic and −4.9 mmHg diastolic (24-hour averages). These translate to moderate within-subject effect sizes (0.5 to 0.65), suggesting a potentially meaningful clinical effect. There was no impact in a smaller group of normotensive participants, no change in nocturnal BP, and no effect on pulse pressure or heart rate. While these effect sizes are clinically relevant for early hypertension, interpretation is limited by the absence of a randomised placebo-controlled design, meaning regression to the mean and behavioural factors cannot be excluded.

Methodologically, the study’s main strength is the use of 24-hour ambulatory BP monitoring, which improves reliability over clinic readings, along with phytochemical characterisation of the intervention. However, it is constrained by a small sample size and lack of blinding and a proper control group. Safety signals were reassuring over the 45 days, with no adverse events and stable biochemistry. Clinically, this study should be viewed as hypothesis-generating: it suggests rosemary infusion may exert modest antihypertensive effects, but requires confirmation in well-powered, randomised, dose-ranging trials before integration into standard care.

Beyond blood pressure, rosemary tea shows a range of emerging clinical effects, particularly in the neurocognitive space. Small human studies suggest improvements in mood, anxiety, and cognitive performance, and notably, a pilot trial has reported a marked increase in circulating brain-derived neurotrophic factor (BDNF) following short-term rosemary tea consumption, pointing to a potential role in neuroplasticity and stress resilience. Mechanistically, this aligns with its polyphenols (such as rosmarinic acid and carnosol) acting via Nrf2, anti-inflammatory and CREB-related pathways (cAMP response element-binding protein). Hence the dried leaf is suitable in this context (since the polyphenols are retained on drying), even though it is lower in essential oil compared to fresh rosemary.

So at this point there is no harm and possibly great benefit in the suggestion that hypertensive patients could start taking rosemary leaf tea as part of their overall regime.

For more information see: https://www.sciencedirect.com/science/article/pii/S2667031325000569?via%3Dihub

09/05/2026

09/05/2026